SecBot SecBot
8-K ·Filed Jun 24, 2026

REVB

REVELATION BIOSCIENCES, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed4mo ago SEC0001193125-26-281200
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

The reverse split authorization (up to 1:250) signals potential Nasdaq compliance efforts, monitor for announcement of specific ratio and timing. The enhanced change-in-control severance provisions may indicate the board is positioning for a sale process. No operating or financial data was provided; wait for the next 10-Q for revenue/cash runway updates.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.9600
T+0 close · Jun 24, 2026 · via day close
Latest settled
−3.08%
T+60 · $0.9304
Vs SPY
−6.81%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 25 $0.9600entry
  2. T+1 · 5mo ago +2.08%α +2.81% · $0.9800
  3. T+5 · 5mo ago +8.33%α +6.77% · $1.04
  4. T+20 · 4mo ago +11.46%α +10.93% · $1.07
  5. T+60 · 8w ago −3.08%α −6.81% · $0.9304
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revelation Biosciences filed an 8-K covering: (1) amended CEO/CFO employment agreements with enhanced change-in-control severance (2x base + bonus, 18-month COBRA, full equity vesting), (2) bylaw amendments adding universal proxy rules, a formal 'Cause' definition, and an emergency CEO/CFO succession framework, and (3) annual meeting results including approval of a reverse stock split (ratio up to 1:250) and ratification of Baker Tilly as auditor. The $4M micro-cap's board is entrenching governance provisions and increasing executive golden parachutes as the company appears to prepare for potential restructuring or a sale process.

Key Facts

  • CEO James Rolke and CFO Chester Zygmont III entered new 3-year employment agreements with 2x base + target bonus change-in-control severance (up from 1x), plus 18-month COBRA and full equity acceleration
  • Stockholders approved a reverse stock split at any ratio between 1:2 and 1:250, within one year, with no further stockholder vote required
  • Bylaws amended to add a formal 'Cause' definition (requiring independent-board determination) and emergency succession for CEO/CFO vacancies
  • Annual meeting votes: 519,169 for Jennifer Carver as Class A director (vs 24,779 against, 263,081 withheld); 1,786,623 for reverse split authorization
  • No financial data (revenue, EPS, margins, cash flow) was provided in the filing
  • Market cap is $4M with 86% analyst bullishness but substantial broker non-votes (1,427,319 on director election) suggesting retail-dominated shareholder base

Financial Impact

No financial data reported in filing. CEO base salary disclosed at $625,000 with 55% target bonus; CFO terms not disclosed. Reverse split authorized up to 1:250, which could significantly affect share count and per-share metrics.

executive compensationshare count (pending reverse split)governance structure

Risk Factors

  • Reverse stock split risks: liquidity reduction, potential secondary offering, warrant adjustment complexities
  • Micro-cap with $4M market cap faces Nasdaq delisting if bid price stays below $1.00
  • Enhanced golden parachutes could reduce board discipline in a sale process
  • No operating revenue reported, cash runway and burn rate are unknown from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-281200
Document: 0001193125-26-281200-index.html0001193125-26-281200
Document: 0001193125-26-281200.txt0001193125-26-281200

Track record

4 reports on REVB

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 13, 20263d ago 8-K Neutral 2/10 Entry $4.27 Now $3.82 −10.43% settles Nov 20
  2. Nov 5, 202611d ago 8-K Bearish 4/10 Entry $3.89 to $4.27 Now $3.82 +1.80% ▼ −9.64% −7.05% vs SPY
  3. Aug 19, 202612w ago 8-K Neutral 3/10 Entry $1.07 to $1.03 Now $3.82 +257.01% ▼ −3.74% −4.85% vs SPY
  4. Jun 24, 202620w ago 8-K Neutral 4/10 Viewing Entry $0.9600 to $1.04 Now $3.82 +297.92% ▲ +8.33% +6.77% vs SPY
Showing 4 of 4

US Market Status

Market Closed · Opens in 8h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 24, 2026